| SINOPHARM-GROUP-CO-LTD |
SINOPHARM-GROUP-CO-LTD |
95%
|
For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh… |
| CHINA-RESOURCES-PHARMACEUTICAL-GROUP-LTD |
CHINA-RESOURCES-PHARMACEUTICAL-GROUP-LTD |
90%
|
For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh… |
| SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD |
SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD |
90%
|
For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh… |
| SINOPHARM-GROUP-CO-LTD-CHINA-RESOURCES-PHARMACEU |
SINOPHARM-GROUP-CO-LTD-CHINA-RESOURCES-PHARMACEU |
85%
|
. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred. Note receivable is also subject to credit risk. The Company mo… |
| GALT |
Galectin Therapeutics Inc. |
72%
|
Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE graph: associated with chronic liver disea… |
| GALT |
Galectin Therapeutics Inc. |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| GLMD |
Galmed Pharmaceuticals Ltd. |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| GLMD |
Galmed Pharmaceuticals Ltd. |
72%
|
Reciprocal relationship from GLMD graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidat… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from LLY graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease… |
| LLY |
Eli Lilly and Company |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| MDGL |
Madrigal Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from MDGL graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MDGL g… |
| MDGL |
Madrigal Pharmaceuticals, Inc. |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| MRK |
Merck & Co., Inc. |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK grap… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidate… |
| NVO |
Novo Nordisk A/S |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| VKTX |
Viking Therapeutics, Inc. |
72%
|
Reciprocal relationship from VKTX graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidat… |
| VKTX |
Viking Therapeutics, Inc. |
72%
|
associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o… |
| ANNUAL-REPORT-SMALLER-REPORTING-COMPANY |
ANNUAL-REPORT-SMALLER-REPORTING-COMPANY |
62%
|
by financing activities 21 1,344 Effect of exchange rate changes on cash 285 50 Net change in cash and cash equivalents $ 431 $ 3,232 Cash Flows from Operating Activities Cash provided by operating a… |
| BEIJING-CONTINENT-PHARMACEUTICALS-CO-LTD |
BEIJING-CONTINENT-PHARMACEUTICALS-CO-LTD |
62%
|
, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state initia… |
| CATALYST-BIOSCIENCES-INC |
CATALYST-BIOSCIENCES-INC |
62%
|
76 ) — — — ( 1,676 ) — ( 1,676 ) Deferred Offering Costs amortization — — — — ( 7 ) — — — ( 7 ) — ( 7 ) Capital injection in a subsidiary — — — — 4,503 — — — 4,503 ( 4,503 ) — Foreign currency transl… |
| CONTINENT-PHARMACEUTICALS-INC |
CONTINENT-PHARMACEUTICALS-INC |
62%
|
invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation. The Company does not have a plan of repatriation of earnings from non-… |
| GC-BIOPHARMA-CORP |
GC-BIOPHARMA-CORP |
62%
|
. F- 12 Long-Term Receivable Catalyst sold its legacy rare bleeding disorder program to GC Biopharma Corp. (“GCBP”) in February 2023. The Company determined that the hold-back from the GCBP asset sal… |
| GNI-GROUP |
GNI-GROUP |
62%
|
invested or will invest the undistributed earnings indefinitely or that the earnings will be remitted in a tax-free liquidation. The Company does not have a plan of repatriation of earnings from non-… |
| GNI-GROUP-LTD |
GNI-GROUP-LTD |
62%
|
, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state initia… |
| GNI-USA-INC |
GNI-USA-INC |
62%
|
76 ) — — — ( 1,676 ) — ( 1,676 ) Deferred Offering Costs amortization — — — — ( 7 ) — — — ( 7 ) — ( 7 ) Capital injection in a subsidiary — — — — 4,503 — — — 4,503 ( 4,503 ) — Foreign currency transl… |
| GYRE-PHARMACEUTICALS-CO-LTD |
GYRE-PHARMACEUTICALS-CO-LTD |
62%
|
Item 1. Financial Statements (Unaudited) : 2 Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 202 5 2 Condensed Consolidated Statements of Operations and Comprehensive (Los… |
| JIANGSU-WANGAO-PHARMACEUTICALS-CO-LTD |
JIANGSU-WANGAO-PHARMACEUTICALS-CO-LTD |
62%
|
Net cash provided by (used in) operating activities $ 1,010 $ (3,641 ) Net cash used in investing activities (474 ) (19,884 ) Net cash provided by financing activities 24,378 2,102 Effect of exchange… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
le long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes under Section 382 occur… |
